

Contact:

Jarrold Longcor
Senior Director Business Development
MaxCyte, Inc.
(301) 944-1700

For Immediate Release

***MaxCyte to Speak at European Stem Cell & Regenerative
Medicine Congress 2007***

“Potentiating the Therapeutic Effect of Stem Cell Product”

Gaithersburg, MD, April 25, 2007 – MaxCyte, Inc., a clinical stage therapeutic company and pioneer in cell loading systems, announces Madhusudan Peshwa, Ph.D., Vice President of Research & Development will be a featured speaker at the European Stem Cell & Regenerative Medicine Congress 2007. The meeting is being held May 1–3, 2007 in London, England.

Dr. Peshwa’s presentation entitled “Potentiating the Therapeutic Effect of Stem Cell Products” will discuss how engineering stem cells can result in a more potent and efficacious therapy and discuss how the company’s platform technology is being utilized in ongoing clinical trials involving engineered stem cells. The session is scheduled for 12:00 p.m. Thursday, May 3, 2007.

About MaxCyte

MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company’s proprietary *ex vivo* cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a Phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addition there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at CBER.

Madhusudan Peshwa, Ph.D.

Madhusudan V. Peshwa, Ph.D., currently serves as Vice President, Research and Development at MaxCyte, Inc. Dr. Peshwa obtained his Ph.D. in Chemical Engineering from the University of Minnesota and his B.Tech. in Chemical Engineering from the Indian Institute of Technology, Kanpur, India. He is a co-author on over 35 scientific publications and is a co-inventor on five, issued or under review, patent applications. Dr. Peshwa currently serves on the Scientific Advisory

Board for the BioProcess Engineering Center at MIT and Immune Cell Therapy, a private biotechnology company.

For more information, visit <http://www.maxcyte.com>.

This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.

###